Working… Menu
Trial record 31 of 2571 for:    "Plasma Cell Neoplasm"

Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00335647
Recruitment Status : Completed
First Posted : June 12, 2006
Last Update Posted : November 6, 2013
Information provided by:
National Cancer Institute (NCI)

Tracking Information
First Submitted Date  ICMJE June 8, 2006
First Posted Date  ICMJE June 12, 2006
Last Update Posted Date November 6, 2013
Study Start Date  ICMJE January 2006
Actual Primary Completion Date April 2008   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 8, 2006)
  • Safety
  • Efficacy
Original Primary Outcome Measures  ICMJE Not Provided
Change History Complete list of historical versions of study NCT00335647 on Archive Site
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma
Official Title  ICMJE A Phase I/IIa, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerance, and Preliminary Activity of Intravenous High-Dose Fluphenazine HCI in Patients With Advanced Multiple Myeloma
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as fluphenazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase I/II trial is studying the side effects and best dose of fluphenazine and to see how well it works in treating patients with refractory advanced multiple myeloma.

Detailed Description


  • Determine the safety of high-dose fluphenazine hydrochloride in patients with refractory advanced multiple myeloma.
  • Determine the pharmacological properties of this drug.
  • Determine the effectiveness of this drug in these patients.

OUTLINE: This is an open-label, dose-escalation study.

Patients receive high-dose fluphenazine hydrochloride IV 3 times on day 1. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of patients receive escalating doses of fluphenazine hydrochloride until the maximum tolerated dose is determined.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Multiple Myeloma and Plasma Cell Neoplasm
Intervention  ICMJE Drug: fluphenazine hydrochloride
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Estimated Enrollment  ICMJE
 (submitted: November 8, 2006)
Original Enrollment  ICMJE Not Provided
Study Completion Date  ICMJE Not Provided
Actual Primary Completion Date April 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE


  • Histologically or cytologically confirmed multiple myeloma

    • Advanced disease
    • Must be refractory to ≥ 2 different methods of standard treatment
  • Measurable disease, defined as serum paraprotein ≥ 1g/L or urine light chain ≥ 200 mg/24 hours
  • No brain involvement or leptomeningeal disease
  • No spinal cord compression unless the following criteria are met:

    • Patient has undergone prior surgery or radiotherapy
    • Neurological findings are ≤ grade 1
    • Patient is off steroids for spinal cord edema or is on a stable regimen of ≤ 10 mg/day of prednisone or equivalent


  • ECOG performance status (PS) 0-2 (ECOG PS 3 allowed if related to skeletal lesions)
  • Life expectancy ≥ 12 weeks
  • Absolute granulocyte count ≥ 1,000/mm^3*
  • Platelet count ≥ 50,000/mm^3*
  • Hemoglobin ≥ 8.0 g/dL* (no transfusion within the past 7 days)
  • AST and ALT ≤ 2.5 times upper limit of normal (ULN)
  • Bilirubin ≤ 2 times ULN
  • Creatinine clearance ≥ 30 mL/min
  • LVEF ≥ 40%
  • QTc < 450 msec
  • No evidence of dysrhythmias on EKG
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No congestive heart failure
  • No angina pectoris
  • No cardiac arrhythmia
  • No uncontrolled hypertension, defined as systolic blood pressure (BP) > 180 mm Hg and/or diastolic BP > 105 mm Hg
  • No myocardial infarction within the past year
  • No active infection
  • No HIV, hepatitis B, or hepatitis C infection
  • No history of psychosis
  • No history of subcortical brain damage
  • No hypersensitivity to fluphenazine hydrochloride or other phenothiazines
  • No history of seizures or extrapyramidal symptoms
  • No other serious illness or medical condition
  • No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or carcinoma in situ of the cervix NOTE: *Patients with values outside of this range due to infiltration by myeloma may be allowed at the discretion of the investigator


  • See Disease Characteristics
  • Recovered from prior therapy
  • At least 21 days since prior chemotherapy, immunotherapy, or radiotherapy
  • At least 21 days since prior and no concurrent systemic steroids

    • Patients who have been taking chronically administered steroids for ≥ 1 month at a dose ≤ 10 mg/day of prednisone or equivalent are eligible
  • At least 28 days since prior investigational agents
  • At least 6 weeks since prior selective serotonin reuptake inhibitors (SSRIs) (a wash-out period equivalent to 5 times the terminal elimination half-life is required for tricyclic antidepressants or norepinephrine reuptake inhibitors)
  • No concurrent SSRIs, tricyclic antidepressants, or norepinephrine reuptake inhibitors
  • No concurrent dialysis therapy
  • No concurrent hematopoietic growth factors except epoetin alfa

    • Treatment with hematopoietic growth factors may be started during study if patient develops or has progressive cytopenia
  • No concurrent anticholinergics or other antipsychotics
  • No concurrent antiseizure drugs except Neurontin for treatment of neuropathy
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00335647
Other Study ID Numbers  ICMJE CDR0000486281
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Immune Control
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account National Cancer Institute (NCI)
Verification Date April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP